Wednesday, May 31Welcome

The auto-injector market is estimated to be worth US$169.74

LUTON, BEDFORDSHIRE, UK, 30 November 2022 (GLOBE NEWSWIRE) — Exactitude Consultancy, the market research and consulting arm of Ameliorate Digital Consultancy Private Limited, has completed the final in-depth research report on the auto-injector market issued. .

global automatic injector market It is projected to reach US$169.74 billion by 2029 from US$41 billion in 2021, at a CAGR of 17.1% from 2022 to 2029.

An autoinjector (or autoinjector) is a medical device used to deliver specific drug doses. The injector was originally designed to reduce the anxiety associated with self-administration of needle-based drug delivery devices. Most auto-injectors are single-use, single-use, spring-loaded syringes. The autoinjector is easy to use and intended for self-administration by patients or for administration by inexperienced staff. The injection site is determined by the drug loaded. However, it is commonly delivered to the thighs or buttocks.

Get Sample Report of Live Auto Injector Market ->


  • Fully disposable AI serves two distinct functions:
  • Flexi-Q EAI: emergency injection for life-threatening situations
  • Pre-planned injections for chronic diseases with Flexi-Q CAI

Compatibility of new AI gadgets is an important aspect in gaining acceptance. FDA requires a threshold analysis to demonstrate compatibility between a submitted drug and an already registered drug. From the user’s perspective, the Flexi-Q product line is similar to other two-step AIs already on the market.


Creating an injectable device with a variable dose of 80IU.

Numerous recent studies have found that the majority of rheumatoid arthritis patients treated with an autoinjector are more comfortable using the device and have better results than those who receive the injections from someone else. I was.

Market overview

Drug self-administration is on the rise due to an increase in lifestyle-related disorders and major advances in oncology and hormone therapy. The use of auto-injectors has enabled patients to receive treatment more independently and autonomously than ever before. Pharmaceutical companies and service providers face many obstacles when it comes to assembling, labeling and packaging these devices. Meeting the growing demand for auto-injectors requires time-efficient and configurable production procedures. Syntegon Technology (formerly Bosch Packaging Technology) offers highly versatile production equipment for the assembly and labeling of numerous auto-injector formats, reducing time to market.

The use of auto-injectors has provided many benefits for both patients and healthcare providers. Easier self-management, less anxiety, better safety, and better compliance.

main player

Mylan NV, Antares Pharma Inc., Ypsomed, Abbvie, Teva Pharmaceuticals. Becton, Dickinson & Company, Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc., and Biogen Inc. are major players in the auto-injector market.

Recent development

  • On November 17, 2022, the U.S. Food and Drug Administration appears poised to approve certain naloxone products for over-the-counter use. This is a move that will help fight the domestic opioid epidemic.
  • On November 1, 2022, the Food and Drug Administration (FDA) expanded approval of Dupixent® (dupilumab) single-dose prefilled pen to include use in pediatric patients 2 years of age and older for the approved indication . Previously, prefilled pens were indicated to be used only by her patients over the age of 12.
  • On May 10, 2022, Stevanato added another drug delivery technology to its portfolio, working with Owen Mumford to offer customers a two-step disposable auto-injector that automatically adapts to different fill volumes.
  • On March 3, 2022, the Food and Drug Administration (FDA) approved Naloxone Autoinjector 10mg (Naloxone Hydrochloride Injection) for use by military personnel and chemical responders for the emergency treatment of individuals 12 years of age and older. did. Potent opioids such as fentanyl analogues as chemical weapons are suspected.
  • February 7, 2022, Antares Pharma has significant expertise in creating custom-designed drug delivery devices tailored to the patient and therapeutic needs. Antares Pharma forges new partnerships through collaboration, innovation and flexibility, leveraging comprehensive medical device and drug development expertise.

industry news

  • On Nov. 25, 2022, Halozyme Therapeutics HALO shares rose 35.1% this year, against an industry decline of 18%.
  • In May 2022, Jabil Healthcare, a division of Jabil Inc., unveiled the Qfinity Automated System, a simple, reusable and modular solution for subcutaneous (SC) drug self-administration at a lower cost than market alternatives. Launched syringe platform.
  • In May 2022, Stevanato Group SpA entered into an exclusive agreement with Owen Mumford Ltd., one of the leading medical device developers and manufacturers, for the Aidaptus autoinjector.

View Full Premium Report ->

Automatic Injector Market Segmentation

based on product

  • Prefilled Auto Injector – Pre-filled auto-injectors will account for a significant share of approximately 91.7% in the global auto-injector market in 2021, and is expected to grow at a staggering CAGR of 21.6% during the forecast period.
  • fillable auto-injector

based on type

  • Disposable self-injector – The disposable auto-injector sector contributed the most during the forecast period, rising at a CAGR of 18.6%.
  • reusable auto-injector
  • based on application
  • rheumatoid arthritis
  • Anaphylaxis – The anaphylaxis segment is expected to grow at the fastest CAGR during the forecast period, with a revenue share of around 88.9% in 2021.
  • multiple sclerosis
  • Other (cardiovascular disease, diabetes, migraine, psoriasis, anemia)

based on end user

  • Home care settings – The home care settings category is expected to contribute the most to market growth, increasing at a CAGR of 18.3% during the forecast period.
  • hospitals and clinics
  • based on administration
  • intramuscular
  • subcutaneous
  • Based on distribution channel
  • hospital pharmacy
  • retail pharmacy
  • Online pharmacy – In 2021, online pharmacies will have the largest market share value of 38.6% in the auto-injector industry.


Stringent regulatory approvals, premium pricing, and product recalls are some of the factors projected to limit market growth during the forecast period.

Increased frequency of product recalls by regulatory agencies such as the US Food and Drug Administration. For example, in September 2021, the U.S. Food and Drug Administration recalled Trulicity auto-injectors manufactured by pharmaceutical company Eli Lilly & Business due to labeling issues. The autoinjector displayed 0.75 mg/0.5 mL even though it contained 1.5 mg/0.5 mL of material.

market driver

Auto-injectors are now routine equipment in medical emergencies, such as emergency treatment for anaphylactic shock. Helps avoid common hazards associated with self-administration via syringe, including improper dose or overuse, serious accidents, and termination of treatment.

Growing demand and penetration of auto-injectors in emerging countries presents significant growth opportunities for the global auto-injectors market. With rapid economic growth and increasing government initiatives in the Asia-Pacific region, prominent auto-injector manufacturers are expanding into the untapped market of the region.

Self-administered medications are primarily used to treat rheumatoid arthritis, diabetes, multiple sclerosis, and other conditions. Self-injection is becoming popular because it eliminates appointments and home visits, saving healthcare providers money. In addition, the use of auto-injectors reduced the patient’s overall medical costs, including hospital visits for each injection.

Regional analysis

  • North America includes the United States, Canada and Mexico
  • Europe includes Germany, France, Great Britain, Italy and Spain
  • South America includes Colombia, Argentina, Nigeria and Chile
  • Asia Pacific includes Japan, China, South Korea, India, Saudi Arabia and Southeast Asia

The world market was dominated by North America. It is growing at a CAGR of 17.9% during the forecast period. Technologically improved products and early acceptance of product approvals, and increasing prevalence of chronic diseases have all contributed to the market growth in the region.

The Asia-Pacific market is expected to grow at a significant CAGR of 18.7% due to the increasing incidence of diabetes and anaphylaxis associated with food allergies.

China and India have great development potential in the auto-injector market during the forecast period. Increased medical awareness, rising healthcare costs, and regulatory attempts to prevent needlestick injuries are expected to drive growth.

Get More Discount On Auto Injector Market ->

There are three FDA-approved glatiramer acetate injectable products on the market, each with its own auto-injector.

  • Copaxone (Teva Pharmaceuticals); Autoject 2
  • Gratopa (sand); Gratopaject
  • Glatiramer Acetate Injection (Beatrice/Mylan); Whisperject

Frequently Asked Questions

  1. What is the growth rate of the global auto-injector market?
  2. Which region has the highest growth rate in the global auto-injector market?
  3. Who Are the Global Key Players in This Automatic Injector Market?
  4. What are the key factors hindering market growth?
  5. What are the key trends in the auto-injector market?

Related reports

Wearable injector market

The global wearable injector market is expected to grow at a CAGR of over 8.3% from 2021 to 2028. From just over US$6.7 billion in 2021, he is expected to exceed US$13.8 billion by 2028.

electronic drug delivery system market

The global electronic drug delivery systems market is expected to grow at a CAGR of 8.1% from 2022 to 2028. From US$7.5 million in 2021, he is expected to exceed US$14.36 million by 2028.

Pharmaceutical delivery market

The global drug delivery market is expected to grow at a CAGR of 5.5% from 2022 to 2029. From US$1.5 billion in 2021, he is expected to reach more than US$2.43 billion by 2029.

Injectable Drug Delivery Market

The global injectable drug delivery market is expected to grow at a CAGR of 6.24% from 2022 to 2029. From US$36.2 billion in 2021, he is expected to reach more than US$62.4 billion by 2029.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *